Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA

BACKGROUND: To date, triple-negative breast cancer (TNBC) treatment options are limited because of the loss of target receptors and, as a result, are only managed with chemotherapy. What is worse is that TNBC is frequently developing resistance to chemotherapy. By using small interfering RNA (siRNA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Long, Mu, Chaofeng, Zhang, Tinghong, Yang, Dejun, Wang, Chenou, Chen, Qiong, Tang, Lin, Fan, Luhui, Liu, Cong, Shen, Jianliang, Li, Huaqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792131/
https://www.ncbi.nlm.nih.gov/pubmed/33413427
http://dx.doi.org/10.1186/s12951-020-00758-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792131/
https://www.ncbi.nlm.nih.gov/pubmed/33413427
http://dx.doi.org/10.1186/s12951-020-00758-4

Ejemplares similares